Bliss GVS Pharma gets revision in credit ratings by Infomerics; Stock trades flat

  • India Infoline News Service |
  • 12 Jan, 2022 |
  • 12:16 PM
IT Stocks Up
Bliss GVS Pharma Limited's credit rating has been revised by Infomerics Valuation and Rating Private Limited with respect to the bank facilities of the company.

The long-term bank facilities Rs84.25cr (increased from Rs70cr) in Exim Bank and Federal Bank have been revised to IVR BBB/ Stable from IVR BBB- / Positive.

The credit rating agency also revised the company’s rating on short-term bank facilities Rs75cr (reduced from Rs90cr) in Federal Bank to IVR A3+ from IVR A3.

At around 12.20 PM, Bliss GVS Pharma Ltd was trading at Rs99.40 per share down by Rs0.05 or 0.05% from its previous closing of Rs99.45 per share on the BSE.

Invest wise with Expert advice

ad IconAd Image

Most Read News

Article Image
  • 14 March, 2022 |
  • 7:03 AM

The US Federal committee's meeting will conclude on March 16, 2022.

Most Shared News

No Record Found